GlassScriptPhysician profile
Rajasree Ajay
NPI 1942257787
$1,874.34
in general payments reported to CMS, 2019-2025
36 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $173 · 2021: $37.51 · 2022: $306 · 2023: $135 · 2024: $340 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.79 |
| Education | $200.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $262.48 | 2019-2025 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $179.93 | 2019-2025 | Enhertu, Calquence |
| Pfizer INC. | $160.78 | 2019-2025 | |
| Incyte Corporation | $111.40 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $86.95 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $80.28 | 2019-2023 | Opdivo |
| Daiichi Sankyo INC. | $69.94 | 2019-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $69.00 | 2022 | |
| Amgen INC. | $56.50 | 2021-2022 | |
| Astellas Pharma US INC | $54.20 | 2019-2023 | Padcev |
| Genentech USA, INC. | $53.77 | 2019-2023 | Gazyva, Venclexta, Polivy |
| Janssen Biotech, INC. | $48.85 | 2019-2024 | Erleada |
| Beigene USA, INC. | $45.48 | 2025 | Brukinsa |
| Genzyme Corporation | $41.90 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $41.28 | 2023-2024 | |
| Eisai INC. | $34.00 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $31.08 | 2020 | |
| Exelixis INC. | $28.13 | 2024-2025 | Cabometyx |
| Abbvie INC. | $26.58 | 2022 | |
| Foundation Medicine, INC. | $26.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.00 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.30 | 2019-2020 | |
| Sirtex Medical INC | $22.97 | 2019 | |
| Array Biopharma INC | $22.68 | 2024 | Mektovi, Tukysa, Braftovi |
| Mirati Therapeutics, INC. | $21.37 | 2024 | Krazati |
| Dova Pharmaceuticals | $18.49 | 2019 | |
| Glaxosmithkline, LLC. | $17.14 | 2025 | Zejula, Jemperli |
| Celgene Corporation | $16.26 | 2019 | |
| Lilly USA, LLC | $14.70 | 2019 | |
| Sobi, INC | $13.84 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $13.44 | 2020 | |
| Coherus Oncology, INC. | $13.16 | 2022 | |
| Verastem, INC. | $11.99 | 2020 | |
| Epizyme, INC. | $11.90 | 2021 | |
| Fortovia Therapeutics, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajasree Ajay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.